treprostinil / Generic mfg. - LARVOL DELTA

Simultaneous Liver-Kidney Transplantation in the Setting of Severe Port-Pulmonary Hypertension (ACG 2026) - "She was on tadalafil 40 mg daily and inhaled treprostinil 80 mcg; prior trials of selexipag and macitentan were discontinued due to intolerance and worsening anemia, respectively. Sotatercept was contraindicated given thrombocytopenia...Despite intolerance or contraindication to several standard pulmonary vasodilators, the patient was bridged to transplant with intravenous treprostinil, renal replacement therapy and careful volume management, to meet hemodynamic listing criteria. This case illustrates the importance of individualized, dynamic risk assessment in PoPH patients."

Cardiovascular • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatology • Immunology • Nephrology • Polycystic Kidney Disease • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis • Transplantation

Parenteral Treprostinil as an Effective Bridge to Lung Transplant in Patients with Severe Pulmonary Hypertension Associated with Interstitial Lung Disease. (PubMed, J Cardiovasc Dev Dis) - "Most patients were successfully bridged to lung transplantation, while only two patients died prior to transplantation. In selected patients with severe PH-ILD, parenteral treprostinil may improve pulmonary hemodynamics and facilitate a successful bridge to lung transplantation without worsening oxygenation."

Journal • Cardiovascular • Heart Failure • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation

EPIH IIT: Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH) (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Valley Health System

New P1 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. (PubMed, Am J Respir Crit Care Med) - P3 | "Inhaled treprostinil slowed the rate of lung function loss, delayed clinical worsening and IPF exacerbations, and demonstrated benefits in DLCO and quality of life over 52 weeks. The results support the use of inhaled treprostinil in patients with IPF.(Funded by United Therapeutics Corp; ClinicalTrials.gov number, NCT04708782 for TETON-1 and NCT05255991 for TETON-2)."

Journal • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Long-Term Subcutaneous Treprostinil in Pediatric Pulmonary Arterial Hypertension at a Latin American Referral Center: A Retrospective Cohort Study. (PubMed, Pulm Circ) - "In this small Latin American referral-center cohort, subcutaneous treprostinil treatment was accompanied by favorable risk transitions and stabilization of right ventricular geometry among long-term survivors. These findings are exploratory and should be interpreted in light of the small sample size, retrospective design, missing longitudinal data, and potential confounding by disease severity, survival, and treatment escalation."

Journal • Retrospective data • Cardiovascular • Hypertension • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

An Early Single-Center Case Series Experience With a Recently Introduced Formulation of Inhaled Treprostinil (Yutrepia). (PubMed, Cureus) - " In this retrospective, single-center case series of Yutrepia, no airway-related dose modifications or discontinuations were documented; however, the 95% confidence interval (0.0%-14.9%) indicates that clinically relevant event rates cannot be excluded given the small sample size. Overall, however, 54.5% of patients experienced an adverse event, 40.9% required dose modification, and 36.4% discontinued treatment because of an adverse event. These findings should not be interpreted as indicating that Yutrepia was broadly well tolerated. The observed frequencies of airway-related adverse events were descriptively lower for some events than those reported in selected previous studies of inhaled treprostinil, but direct comparisons cannot be made because of differences in study populations, designs, follow-up, and adverse event ascertainment. Given the small sample size and retrospective design, these findings are hypothesis-generating, and larger prospective studies are..."

Journal • Cardiovascular • Cough • Fatigue • Hypertension • Hypotension • Interstitial Lung Disease • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Late Breaking Abstract - Inhaled Treprostinil does not improve exercise tolerance in patients with mild COPD (ERS 2026) - "iTRE decreased exercise tolerance in mild COPD without affecting ventilatory efficiency and dyspnea, while potentiating exercise blood pressure responses. These data suggest that iTRE is not a viable therapeutic target to improve functional capacity in mild COPD. Supported by United Therapeutics"

Clinical • Late-breaking abstract • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Late Breaking Abstract - The effect of inhaled treprostinil in patients with idiopathic pulmonary fibrosis using a win ratio analysis (ERS 2026) - "Win ratio analyses favored iTRE, confirming benefits in preventing CWE in patients with IPF, such as death, AE-IPF and RH."

Clinical • Late-breaking abstract • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Antifibrotic Actions of Treprostinil (ERS 2026) - "Sponsored by Ferrer"

Idiopathic Pulmonary Fibrosis

Clinical and haemodynamic determinants of response to pulmonary vasodilators in pulmonary hypertension associated with interstitial lung disease (ERS 2026) - "With the exception of inhaled treprostinil, most trials of pulmonary vasodilators (PVDs) in PH-ILD have shown limited benefit. In PH-ILD, greater baseline PH severity is linked to greater PVR reduction on PVD therapy. While PVR reduction reflects improved 6MWD and WHO-FC, CI improvement serves as the key marker for survival. Baseline FVC was not associated with response, supporting the consideration of PVD therapy regardless of pulmonary function, provided that PH is severe."

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Survival in patients with pulmonary hypertension (PH) associated with interstitial lung diseases receiving therapies approved for PH (ERS 2026) - "This prospective study confirms the dismal prognosis of PH-ILD and does not suggest a one-year survival benefit from treatment with PDE5i or inhaled treprostinil."

Clinical • Cardiovascular • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Improvements in lung function among idiopathic pulmonary fibrosis patients treated with inhaled treprostinil (ERS 2026) - "Progressive FVC decline is a hallmark of IPF. Although a small proportion of patients stabilize or improve over time, treatment with inhaled treprostinil led to a greater proportion of patients experiencing an improvement in FVC at 52 weeks when compared to placebo. Table 1."

Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

The acute effects of treprostinil dry powder inhaler on stroke volume augmentation and dead space ventilation in patients with exercise-induced pulmonary hypertension (ERS 2026) - "Inhaled treprostinil given 30 minutes before exercise improved stroke volume augmentation in EiPH. Phase 2, completing March 2026, will clarify effects on symptoms and physiologic response at maximally tolerated dosing."

Clinical • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Continuous intravenous Treprostinil in advanced pulmonary arterial hypertension: Experiences from a single-centre long-term registry (ERS 2026) - "Continuous intravenous administration of treprostinil via the LenusPro® pump proved to be an effective treatment option for patients with advanced PAH in this monocentric cohort and led to haemodynamic improvements.Prospective multicentre studies are needed to validate the long-term clinical benefits of this therapy."

Clinical • Metastases • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

ARTISAN interim analysis: early high-dose treprostinil reduces mPAP and improves pulmonary arterial hypertension risk profile (ERS 2026) - P4 | "Conclusions Early initiation, rapid escalation to high-dose TRE led to significant reductions in mPAP, with notable improvements in RV function, risk assessments, and NT-proBNP at 12 months. Sponsored by United Therapeutics."

Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Effect of inhaled treprostinil dosing in patients with idiopathic pulmonary fibrosis enrolled in the TETON IPF program (ERS 2026) - "Patients with IPF receiving doses of 9 bps or more of iTRE experienced greater improvement in FVC. These findings are consistent with prior dose response analyses of iTRE and align with currently approved dosing recommendations. Sponsored by United Therapeutics Corporation"

Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE: A SYSTEMATIC REVIEW (CHEST 2026) - No abstract available

Review • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

7112: Time to Look Closer: Emerging Data and Screening Insights in PH-ILD (CHEST 2026) - "This session will spotlight screening considerations and explore how providers can apply these insights in practice. Attendees will also review the clinical data for inhaled treprostinil in PH-ILD and examine how earlier recognition may create more opportunities to support patient care."

Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

7105: YUTREPIA® (treprostinil) Inhalation Powder: A Prostacyclin Treatment for Your PAH and PH-ILD Patients (CHEST 2026) - "Sponsored by Liquidia Technologies, Inc. Description This presentation will explore YUTREPIA, the first and only dry powder formulation of treprostinil enabled by PRINT Technology approved for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)."

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

SEVERE CTEPH IN PREGNANCY: BRIDGING WITH TREPROSTINIL TO DELIVERY AND SURGICAL CURE (CHEST 2026) - No abstract available

Cardiovascular

Translation study to document application of treprostinil for minimizing ischemia-reperfusion injury in donation after circulatory death livers using normothermic machine perfusion (TTS 2026) - "Treprostinil supplementation during NMP of DCD livers significantly reduced IRI and improved hepatobiliary function. These findings provide strong mechanistic and functional support for clinical translation. An ongoing pilot study with human DCD livers aims to translate these finding into clinical practice and enhance utilization of marginal grafts."

Cardiovascular • Hepatology • Reperfusion Injury • ICAM1 • NOS3 • TNFA

ASSOCIATION OF HEART RATE RECOVERY AND TREATMENT RESPONSE WITH INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (CHEST 2026) - No abstract available

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

FROM BENCH TO BREATH WITH INHALED TREPROSTINIL POWDER: AN EARLY SINGLE-CENTER CASE SERIES CLINICAL EXPERIENCE (CHEST 2026) - No abstract available

Clinical • Cardiovascular

EFFICACY, SAFETY, AND TOLERABILITY OF TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION (PAH): A SYSTEMATIC REVIEW AND META-ANALYSIS (CHEST 2026) - No abstract available

Retrospective data • Review • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

EFFICACY OF INHALED TREPROSTINIL ON MULTIPLE DISEASE PROGRESSION EVENTS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN THE TETON-IPF PROGRAM (CHEST 2026) - No abstract available

Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases